Evidence map›Paper›PMID 36396738›Full record

ArticleCancer immunology, immunotherapy : CII2023

Improved MAIT cell functions following fecal microbiota transplantation for metastatic renal cell carcinoma.

Marina Ninkov, Crystal L Schmerk, Manoosh Moradizadeh, Seema N Parvathy, Rene Figueredo, Jeremy P Burton, Michael S Silverman, Ricardo Fernandes, Saman Maleki Vareki, S M Mansour Haeryfar

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer immunology, immunotherapy : CII, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 1 pooled it
2.2field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. The microbiota and renal cell carcinoma.Cellular oncology (Dordrecht, Netherlands) · 2024
    Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Marina NinkovDepartment of Microbiology and Immunology, Western University, 1151 Richmond Street, London, ON, N6A 5C1, Canada.
Crystal L SchmerkDepartment of Microbiology and Immunology, Western University, 1151 Richmond Street, London, ON, N6A 5C1, Canada.
Manoosh MoradizadehDepartment of Surgery, Division of General Surgery, Western University, London, ON, Canada.
Seema N ParvathyDepartment of Medicine, Division of Infectious Diseases, Western University, London, ON, Canada.
Rene FigueredoDepartment of Oncology, Western University, London, ON, Canada.
Jeremy P BurtonDepartment of Microbiology and Immunology, Western University, 1151 Richmond Street, London, ON, N6A 5C1, Canada.
Michael S SilvermanDepartment of Medicine, Division of Infectious Diseases, Western University, London, ON, Canada.
Ricardo FernandesDepartment of Oncology, Western University, London, ON, Canada.
Saman Maleki VarekiDepartment of Oncology, Western University, London, ON, Canada. Saman.MalekiVareki@lhsc.on.ca.
S M Mansour HaeryfarDepartment of Microbiology and Immunology, Western University, 1151 Richmond Street, London, ON, N6A 5C1, Canada. Mansour.Haeryfar@schulich.uwo.ca.ORCID http://orcid.org/0000-0002-1125-8176
Western University · CA

Funding

Canadian Cancer Society Innovation Grant 706396London Regional Cancer Program Keith Samitt Translational Research Catalyst Grant
6 · The paper itself

Abstract

Strategies to modify the gut microbiome in cancer patients using fecal microbiota transplantation (FMT) have gained momentum as a therapeutic intervention. However, how FMT impacts innate-like, antimicrobial T lymphocytes is unclear. In this study, we assessed peripheral blood (PB) mucosa-associated invariant T (MAIT) cell frequencies and functions in patients with metastatic renal cell carcinoma (mRCC) before and seven days after they received FMT as part of a clinical trial. We found comparable MAIT cell frequencies in healthy controls and mRCC patients. In contrast, γδ T cells exhibited a numerical decline in mRCC, which was partially reversed by FMT. We also found a significant increase in the PB CD4

Indexed as

Carcinoma, Renal CellKidney NeoplasmsMucosal-Associated Invariant T CellsFecal Microbiota TransplantationHumansInterleukin-12Interleukin-18Interleukin-12Interleukin-18CytokineFecal microbiota transplantationKidney cancerMAIT cellsMR1Renal cell carcinoma

Identifiers

PMID36396738
PMCPMC9672546
OpenAlexW4309260043

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.